Single gene mutations in LRP1B were found to be associated with high TMB in lung cancer (Lan et al., 2019), which may be associated with favorable outcomes with immune checkpoint inhibitors (Brown et al., 2021). This evidence concerns the gene LRP1B and lung carcinoma.